Previous 10 | Next 10 |
2024-01-26 12:01:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%. Y...
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM ( F ollow-up, O p...
2024-01-24 09:36:36 ET More on Cytokinetics Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout ...
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024. Title: Effect of Aficamten on Structure and Function ...
2024-01-12 15:00:30 ET More on the markets S&P 500: Traders Buy, Investors Sell Recession Forecasting - The Business Cycle Back To 1928 (Part 2) 2024 Analyst Outlook: Victor Dergunov On Undervalued Sectors Uncovering New Year Opportunities Investors were ...
2024-01-12 06:52:07 ET Summary Hertz's decision to sell off its electric vehicle fleet contributes to a decline in share prices for EV companies like Tesla, Rivian, and Fisker. Toyota's stock rises while other automakers, including Ford and General Motors, see negative territory. ...
2024-01-11 23:54:22 ET Summary Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to Camzyos, implying that it could become a blockbust...
2024-01-11 15:37:25 ET Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript Cytokinetics plunges a...
2024-01-11 12:44:34 ET More on Cytokinetics Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript ...
2024-01-11 12:30:39 ET Gainers: Atreca ( BCEL ) +103% . First Financial Northwest ( FFNW ) +41% . SEALSQ Corp ( LAES ) +42% . Sagimet Biosciences ( SGMT ) +33% . Moolec Science SA ( MLEC ) +29% . Swvl Holdings Corp ( SWVL ...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...
2024-06-04 10:30:05 ET B. Riley analyst issues BUY recommendation for CYTK on June 4, 2024 08:58AM ET. The previous analyst recommendation was Buy. CYTK was trading at $49.018 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...